Table 1.

Screening Strategies for Pharmacologic Treatment

Strategy	Category	Criteria for Positive Screen	Origin of Guideline/Strategy
Clinical Fracture	Clin Fx	Major osteoporotic fracture of the hip or vertebrae	NOF (25)
Clinical Fracture or Bone Mineral Density	Clin Fx or BMD	Major osteoporotic fracture of the hip or vertebrae or Bone mineral density (by Dual X-ray Absorptiometry, DXA): hip (femoral neck or total hip) or spine T-score ≤ −2.5 (osteoporosis range)	NOF (25)
Clinical Fracture, Bone Mineral Density or Vertebral Fracture	Clin Fx, BMD or VF	Major osteoporotic fracture of the hip or vertebrae or Bone mineral density (by Dual X-ray Absorptiometry, DXA): hip (femoral neck or total hip) or spine T-score ≤ −2.5 (osteoporosis range) or Vertebral fracture determined by vertebral fracture assessment (DXA derived)	NOF (25)
FRAX using Femoral Neck Bone Mineral Density	FRAX-FN	FRAX calculation using femoral neck BMD: Low bone mass and a WHO 10 year probability of hip fracture ≥ 3% or 10 year probability of any major osteoporotic related fracture ≥ 20%	NOF (25) WHO (39)
FRAX using Body Mass Index	FRAX-BMI	FRAX calculation using only height and weight: with WHO 10 year probability of hip fracture ≥ 3% or 10 year probability of any major osteoporotic related fracture ≥ 20%	NOF (25) WHO (39)
Clinical Fracture or Heel Ultrasound	Clin Fx Or Heel US	Major osteoporotic fracture of hip or vertebrae or Heel ultrasound T-score ≤ −2.5	NOF (25) NOF-Ultrasound predicts fracture risk, T- scores not equivalent to DXA (25)